MX2022012967A - Tratamiento de la hidradenitis supurativa. - Google Patents

Tratamiento de la hidradenitis supurativa.

Info

Publication number
MX2022012967A
MX2022012967A MX2022012967A MX2022012967A MX2022012967A MX 2022012967 A MX2022012967 A MX 2022012967A MX 2022012967 A MX2022012967 A MX 2022012967A MX 2022012967 A MX2022012967 A MX 2022012967A MX 2022012967 A MX2022012967 A MX 2022012967A
Authority
MX
Mexico
Prior art keywords
hidradenitis suppurativa
treatment
administering
treated
agent
Prior art date
Application number
MX2022012967A
Other languages
English (en)
Inventor
John Simard
Bruce Randazzo
Ernesto Munoz
Yanli Zhuang
Bhaskar Srivastava
Karen Keefe
Swaroopa Paratkar
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022012967A publication Critical patent/MX2022012967A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

La hidradenitis supurativa puede tratarse al administrar una composición farmacéutica que incluye un portador farmacéuticamente aceptable y una cantidad terapéuticamente efectiva de un agente que se une selectivamente a IL-1¿.
MX2022012967A 2020-04-16 2021-04-16 Tratamiento de la hidradenitis supurativa. MX2022012967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010923P 2020-04-16 2020-04-16
PCT/US2021/027614 WO2021211927A1 (en) 2020-04-16 2021-04-16 Treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
MX2022012967A true MX2022012967A (es) 2023-01-18

Family

ID=75870730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012967A MX2022012967A (es) 2020-04-16 2021-04-16 Tratamiento de la hidradenitis supurativa.

Country Status (10)

Country Link
US (1) US20230235042A1 (es)
EP (1) EP4135839A1 (es)
JP (1) JP2023522196A (es)
KR (1) KR20230004638A (es)
CN (1) CN115702023A (es)
AU (1) AU2021257453A1 (es)
BR (1) BR112022020882A2 (es)
CA (1) CA3179228A1 (es)
MX (1) MX2022012967A (es)
WO (1) WO2021211927A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196916A1 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating of hidradenitis suppurativa
US12119118B2 (en) * 2022-12-09 2024-10-15 BelleTorus Corporation Compute system with hidradenitis suppurativa severity diagnostic mechanism and method of operation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3085773B1 (en) 2008-05-30 2020-03-18 XBiotech, Inc Uses of il-1 alpha antibodies
ES2697056T3 (es) * 2011-04-01 2019-01-21 Xbiotech Inc Tratamiento para patologías dermatológicas
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
EP2914268B1 (en) 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
KR102015451B1 (ko) 2014-06-03 2019-08-28 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
BR112022020882A2 (pt) 2023-05-02
EP4135839A1 (en) 2023-02-22
US20230235042A1 (en) 2023-07-27
KR20230004638A (ko) 2023-01-06
JP2023522196A (ja) 2023-05-29
CA3179228A1 (en) 2021-10-21
AU2021257453A1 (en) 2022-11-03
CN115702023A (zh) 2023-02-14
WO2021211927A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
MX2022012967A (es) Tratamiento de la hidradenitis supurativa.
MX2020010322A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
GB2475013A (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
WO2018102687A3 (en) Combination therapy for treating cancer
MX2023013403A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
MX2024002561A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
ZA202212283B (en) Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
MX2022011231A (es) Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
NZ751972A (en) Treatment of prurigo nodularis
BR112022025920A2 (pt) Tratamento de artrite reumatoide
MX2021010402A (es) Tratamiento de la hidradenitis supurativa.
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
WO2021161319A8 (en) Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.